Prick Or Treat: A Case Of Systemic Reaction During Intradermal Tests With Beta-Lactams

This study investigated the response of 61 patients with locally advanced or multiple basal cell carcinoma (BCC) to vismodegib treatment. The results showed that no specific factors predicted the response to vismodegib. However, the median progression-free survival was 69.5 months. Multiple BCC was associated with a higher risk of relapse, while longer treatment duration reduced this risk. Among the 20 patients who relapsed, 15 were re-treated with vismodegib, achieving a 66% response rate. The study concluded that increased treatment duration was linked to a decreased risk of relapse, although predictive factors for response were not identified.